3 weeks BioMarin (BMRN) Upgraded to Buy: Here’s WhyZacks
BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Biomarin Pharma (BMRN) · Current · Earnings
X